Humana (HUM) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Humana (HUM) has outperformed Labcorp (LH) over the past year, gaining 34.3% versus a gain of 11.6%. Over five years, LH leads with a +33.7% price change compared with -10.1% for HUM. Humana is the larger company by market cap ($47.61 billion vs $25.30 billion), about 1.9 times the size.
On valuation, Labcorp trades at a lower forward P/E (15.7x vs 23.9x for Humana). Labcorp offers the higher dividend yield (0.92% vs 0.89%). Labcorp converts more of its revenue into profit, with a net margin of 6.3% versus 0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | LH |
|---|---|---|
| Share price | $396.51 | $311.97 |
| Market cap | $47.61B | $25.30B |
| 1-day change | -1.92% | +0.08% |
| YTD return | +54.81% | +24.35% |
| 1-year return | +34.30% | +11.57% |
| 5-year return | -10.09% | +33.70% |
| P/E ratio (TTM) | 37.48 | 25.80 |
| Forward P/E | 23.90 | 15.73 |
| EPS (TTM) | $10.58 | $12.09 |
| Dividend yield | 0.89% | 0.92% |
| Annual dividend | $3.54 | $2.88 |
| Revenue (latest FY) | $129.66B | $13.95B |
| Revenue growth (YoY) | +10.11% | +7.25% |
| Net income (latest FY) | $1.19B | $876.50M |
| Gross margin | — | 28.76% |
| Operating margin | 2.09% | 9.92% |
| Net margin | 0.92% | 6.28% |
| 52-week high | $428.88 | $341.80 |
| 52-week low | $163.11 | $244.52 |
| Distance from 52-week high | -7.55% | -8.73% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +6.87% | +10.33% |
| Average volume | 1.23M | 740.44K |
| Shares outstanding | 120.08M | 81.10M |
| Employees | 67,060 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUM has outperformed LH by 22.7 percentage points over the past year.
- Humana trades at a higher earnings multiple (37.5x vs 25.8x trailing P/E).
- Labcorp is more profitable, keeping 6.3 cents of every revenue dollar as net income versus 0.9 cents for Humana.
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
HUM vs LH FAQ
Which is bigger, Humana or Labcorp?
Humana (HUM) is larger, with a market capitalization of $47.61B compared with $25.30B for Labcorp (LH).
Which stock has performed better over the past year, HUM or LH?
HUM returned +34.30% over the past 12 months, compared with +11.57% for LH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HUM or LH?
LH has the lower trailing P/E at 25.8, versus 37.5 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Humana or Labcorp?
Labcorp has the higher yield at 0.92%, compared with 0.89% for Humana.
Are Humana and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.